IDEAYA Biosciences (IDYA) Stock Price, News & Analysis

Company Overview

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Key Stats

• Today's Range: $24.74 to $25.39
• 50-Day Range: $21.02 to $25.35
• 52-Week Range: $13.45 to $40.25
• Volume: 503,894 shs
• Average Volume: 895,753 shs
• Market Capitalization: $2.18 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $47.10
• Consensus Rating: Moderate Buy

IDEAYA Biosciences Stock Analysis - MarketRank™

IDEAYA Biosciences scored higher than 89% of companies evaluated by MarketBeat, and ranked 129th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

IDEAYA Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 9 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

IDEAYA Biosciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for IDEAYA Biosciences are expected to decrease in the coming year, from ($3.07) to ($3.20) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of IDEAYA Biosciences is -6.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of IDEAYA Biosciences is -6.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

IDEAYA Biosciences has a P/B Ratio of 2.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

12.57% of the float of IDEAYA Biosciences has been sold short.

Short Interest Ratio / Days to Cover

IDEAYA Biosciences has a short interest ratio ("days to cover") of 8.8.

Change versus previous month

Short interest in IDEAYA Biosciences has recently decreased by 13.80%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

IDEAYA Biosciences does not currently pay a dividend.

Dividend Growth

IDEAYA Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -1.19

Percentage of Shares Shorted

12.57% of the float of IDEAYA Biosciences has been sold short.

Short Interest Ratio / Days to Cover

IDEAYA Biosciences has a short interest ratio ("days to cover") of 8.8.

Change versus previous month

Short interest in IDEAYA Biosciences has recently decreased by 13.80%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 1.53

News Sentiment

IDEAYA Biosciences has a news sentiment score of 1.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for IDEAYA Biosciences this week, compared to 6 articles on an average week.

Search Interest

Only 4 people have searched for IDYA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, IDEAYA Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.50% of the stock of IDEAYA Biosciences is held by insiders.

Percentage Held by Institutions

98.29% of the stock of IDEAYA Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

IDYA Stock Analysis - Frequently Asked Questions

How have IDYA shares performed this year?

IDEAYA Biosciences' stock was trading at $25.70 on January 1st, 2025. Since then, IDYA stock has decreased by 3.0% and is now trading at $24.93.

How were IDEAYA Biosciences' earnings last quarter?

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) released its earnings results on Tuesday, August, 5th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.85) by $0.03. The business's quarterly revenue was up NaN% on a year-over-year basis.

When did IDEAYA Biosciences IPO?

IDEAYA Biosciences (IDYA) raised $70 million in an IPO on Thursday, May 23rd 2019. The company issued 5,000,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, Citigroup and Jefferies acted as the underwriters for the IPO.

Who are IDEAYA Biosciences' major shareholders?

IDEAYA Biosciences' top institutional shareholders include Federated Hermes Inc. (5.28%), State Street Corp (3.86%), Sofinnova Investments Inc. (2.45%) and Geode Capital Management LLC (2.41%). Insiders that own company stock include Yujiro S Hata, Briseno Andres Ruiz, Paul A Stone, Michael Anthony White and Jason Throne.
View institutional ownership trends.

How do I buy shares of IDEAYA Biosciences?

Shares of IDYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of IDEAYA Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that IDEAYA Biosciences investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), e.l.f. Beauty (ELF) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 8/05/2025
• Today: 8/28/2025
• Next Earnings (Estimated): 11/03/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IDYA
• CIK: 1676725
• Web: www.ideayabio.com
• Phone: (650) 443-6209
• Fax: N/A
• Employees: 80
• Year Founded: N/A

Price Target and Rating

• Average Price Target for IDEAYA Biosciences: $47.10
• High Price Target: $72.00
• Low Price Target: $25.00
• Potential Upside/Downside: +88.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.79)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$274.48 million
• Net Margins: N/A
• Pretax Margin: -4,740.03%
• Return on Equity: -31.42%
• Return on Assets: -29.45%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.39
• Quick Ratio: 12.39

Sales & Book Value

• Annual Sales: $7 million
• Price / Sales: 312.12
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $10.95 per share
• Price / Book: 2.28

Miscellaneous

• Outstanding Shares: 87,640,000
• Free Float: 85,453,000
• Market Cap: $2.18 billion
• Optionable: Optionable
• Beta: 0.09